dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Zionexa completes a second $5 million capital raise

SNMMI and ACR collaborate on clinical data registry for nuclear medicine

New PET imaging biomarker could better predict progression of Alzheimer's disease

MILabs installs new E-Class SPECT/CT system to enhance heart failure research at CHFC in Germany

Nordion and BRIT collaborate to bring cobalt-60 from India to global markets

Bruce Power completes harvest of Cobalt-60 that will save lives through cancer treatments

Nordion and Tong Xing expand cobalt-60 supply agreement

Advanced imaging technology predicts cardiovascular risk from inflammation detected in arteries

TRIUMF receives historic investment in 2019 federal budget

Enigma Biomedical Group signs license agreement with Merck for novel MK-6884 imaging agent

Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group

Press releases may be edited for formatting or style
Clermont-Ferrand (France), April 11 2018 - Cyclopharma, specialized in molecular imaging solutions, is planning to divest its manufacturing assets and radiopharmaceutical drugs production and commercialization activities in France to Curium group, a world-class company specialized in the development, production and commercialization of tracers for nuclear medicine imaging.

Cyclopharma, created in 2000, based in Clermont-Ferrand (France), develops, produces and distributes diagnostic oncologic, neurologic and cardiac imaging drugs to healthcare professionals. Acquired by Denos in 2013, Cyclopharma employs more than a hundred employees, at its 7 production and R&D sites in France. Today, Cyclopharma is a leader in molecular imaging, a technique which improves patients’ quality of life, efficacy of treatment while reducing costs.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Curium was created in January 2017 by uniting IBA Molecular and Mallindkrodt Nuclear Medicine LLC and has made a stock purchase offer to acquire Cyclopharma from Denos. With this proposed acquisition, Curium intends to increase its production capabilities to provide their customers optimal access to the tracers, meeting growing product demand. Curium would integrate the acquired production facilities into their existing radiopharmaceutical manufacturing network. This enhanced network would enable the commercial production of new compounds, as well as support the development of new products.

Upon the completion of the offer, R&D and international activities of Cyclopharma would be transferred to a dedicated subsidiary which would be owned and managed by Denos. The subsidiary would take over Cyclopharma’s current R&D projects, and commercialize those molecules in France and worldwide directly or with industrial partners.

The divestiture of the manufacturing assets and French commercial activities will allow the management and development team to focus on the new company’s mission of developing and commercializing best-in-class molecular imaging and therapy drugs. The new entity would be based in both France and the United-States. The international presence will build a strong platform for developing and commercializing products.

The first goal of the new company will be to launch EstroTep®, a new radiopharmaceutical tracer bringing an innovative approach for breast cancer diagnosis in Europe, and seek FDA clearance in the US. EstroTep® is considered by the scientific and medical community as a useful tool in the management of breast cancer.


About Cyclopharma
Since its creation in 2000, Cyclopharma has developed molecular imaging solutions to allow the observation of cell function in vivo as part of the targeted treatment of cancer, in order to improve individualized treatment plans for patients in terms of diagnostics, monitoring and therapeutic effectiveness, whilst also reducing costs.

With more than 120 employees and revenue of €23 million, Cyclopharma invests more than 10% of revenue in research into novel molecular imaging tracers. Since 2015 it has built on dense and balanced geographical coverage to drive international growth, with the aim of becoming a major European force in personalized medicine.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED